Article Information
History
- September 2, 2021.
Article Versions
- Version 1 (July 13, 2021 - 09:42).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Ruben Rose1,†,
- Franziska Neumann2,†,
- Olaf Grobe2,
- Thomas Lorentz2,
- Helmut Fickenscher1 and
- Andi Krumbholz1,2,*
- 1Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, Germany
- 2Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany
- ↵*Correspondence: krumbholz{at}infmed.uni-kiel.de; Tel.: +49-431-22010131
↵† These first authors contributed equally
Posted September 02, 2021.
The anti-SARS-CoV-2 immunoglobulin G levels and neutralising capacities against alpha and delta virus variants of concern achieved after initial immunisation with vector vaccine followed by mRNA vaccine boost are comparable to those after double immunisation with mRNA vaccines
